Naiyer A. Rizvi, MD

Name: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
Start: 2025-09-07T18:30:00+02:00
End: 2025-09-07T19:30:00+02:00

August 1, 2017

|

By

|

Estimated Read Time:

1 minute

Names & News

Naiyer A. Rizvi, MD, was named to the ARMO BioSciences, Inc., Board of Directors, Redwood City, US. Dr. Rizvi is Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy, Division of Hematology and Oncology, Columbia University Medical Center, NY, US, and holds the Price Chair in Clinical Translational Research.

About the Authors

Share this Article:

Naiyer A. Rizvi, MD

Recent Posts

Meet Us in Barcelona: What to Expect at the World Conference on Lung Cancer

Celebrate the IASLC Foundation’s Impact

Step it Up at WCLC 2025 in Barcelona

Know Before You Go: Your Guide to Navigating Barcelona

IS03: Satellite EBAC/CME Symposium by Answers in CME: Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC